VANCOLED

Post-LOE

vancomycin hydrochloride

Hikma

ANDAINJECTIONINJECTABLE

Approved

Jul 1986

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

VANCOLED (vancomycin hydrochloride) by Hikma is clinical pharmacology vancomycin is poorly absorbed after oral administration. Approved for serious, severe infections caused by susceptible strains of methicillin-resistant (β-lactam-resistant) staphylococci. First approved in 1986.

Drug data last refreshed 18h ago

Mechanism of Action

CLINICAL PHARMACOLOGY Vancomycin is poorly absorbed after oral administration. In subjects with normal kidney function, multiple intravenous dosing of 1 g of vancomycin (15 mg/kg) infused over 60 minutes produces mean plasma concentrations of approximately 63 mcg/mL immediately after the completion…

Worked on VANCOLED at Hikma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

VANCOLED

Mechanism of Action

Indications (2)